Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00710580 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

BIOLOGICAL: ABT-874
BIOLOGICAL: etanercept
DRUG: placebo

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]